Hualan Biological Engineering, Inc. (002007.SZ) announced that the marketing authorization application for Trastuzumab for Injection of its affiliated company has been accepted.
Hualan Biological Engineering, Inc. (002007.SZ) announced that on September 22, 2026, its affiliated company Hualan Ankang Biotechnology Co., Ltd. received a Notice of Acceptance issued by the National Medical Products Administration, and its marketing authorization application for Trastuzumab for Injection has been accepted. Trastuzumab for Injection is a monoclonal antibody targeting HER2, with the original brand name Herceptin. It is a core first-line treatment for HER2-positive breast cancer and gastric cancer, with broad clinical application and significant market demand.
Hualan Biological Engineering, Inc. (002007.SZ) announced that on September 22, 2026, its affiliated company Hualan Ankang Jinyu Bio-Technology Co., Ltd. received a Notice of Acceptance issued by the National Medical Products Administration, and its marketing authorization application for Trastuzumab for Injection has been accepted. Trastuzumab for Injection is a monoclonal antibody targeting HER2, with the original brand name Herceptin. It is a core first-line treatment for HER2-positive breast cancer and gastric cancer, with broad clinical application and substantial market demand.
Related Articles
Changshu Tianyin Electromechanical (300342.SZ) establishes wholly-owned subsidiary Tianyin Xingfu to expand radar and aerospace electronics business.
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-7172 tablets and others received drug clinical trial approval notices.
Zijin Longking (600388.SH) plans to invest approximately US$55.24 million to build a solar-plus-storage project for the underground mining plant at the Aurora Gold Mine in Guyana.
Changshu Tianyin Electromechanical (300342.SZ) establishes wholly-owned subsidiary Tianyin Xingfu to expand radar and aerospace electronics business.
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-7172 tablets and others received drug clinical trial approval notices.
Zijin Longking (600388.SH) plans to invest approximately US$55.24 million to build a solar-plus-storage project for the underground mining plant at the Aurora Gold Mine in Guyana.
